A phase III randomised controlled trial of single-dose triple therapy in COPD: The IMPACT protocol

European Respiratory Journal

Volumn 48, Issue 2, 2016, Pages 320-330

  Pascoe, Steven J ^a   Lipson, David A ^a,b   Locantore, Nicholas ^a   Barnacle, Helen ^c   Brealey, Noushin ^c   Mohindra, Rajat ^c   Dransfield, Mark T ^d   Pavord, Ian ^e   Barnes, Neil ^c,f  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE; FLUTICASONE FUROATE PLUS UMECLIDINIUM PLUS VILANTEROL; FLUTICASONE FUROATE PLUS VILANTEROL; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

ADULT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SYMPTOM; TREATMENT DURATION; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; PRACTICE GUIDELINE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES;

EID: 84979994372     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02165-2015     Document Type: Review

References (32)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379: 1341-1351.
2. WHO. Deaths from chronic respiratory diseases. www.who.int/gho/ncd/mortality-morbidity/chronic-respiratory-diseases-text/en/ Date last accessed: October 21, 2015. Date last updated: 2015.
3. Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations and hospital admissions in COPD. Chest 2013; 143: 1444-1454.
4. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
5. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.org/ Date last accessed: October 21, 2015. Date last updated: 2015.
6. Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD 2011; 8: 206-243.
7. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir Med 2013; 1: 210-223.
8. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicenter randomized controlled trial. Lancet 2015; 385: 857-866.
9. Vestbo J, Agusti A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014; 189: 1022-1030.
10. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010; 7: 32-43.
11. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
12. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-442.
13. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 523-525.
14. Kew KM, Seniukovich A. Do inhaled steroids increase the risk of pneumonia in people with chronic pulmonary disease (COPD)? www.cochrane.org/CD010115/AIRWAYS-do-inhaled-steroids-increase-the-risk-of-pneumonia-inpeople-with-chronic-obstructive-pulmonary-disease-copd Date last accessed: October 21, 2015. Date last updated: 2015.
15. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-442.
16. Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016; 47: 1374-1382.
17. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
18. Wurst KE, Bushnell G, Shukla A, et al. Factors associated with time to triple therapy in newly diagnosed COPD patients in the UK general practice research database. Pharmacoepidemiol Drug Saf 2013; 22: 33.
19. Wedzicha JA, Decramer M, Ficker, JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA 149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
20. Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax 2015; 70: 519-527.
21. Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012; 106: 382-389.
22. Siler TM, Kerwin E, Sousa AR, et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med 2015; 109: 1155-1163.
23. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
24. Agusti A, Calverley PM, Decramer M, et al. Prevention of exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. J COPD Foundation 2014; 1: 166-184.
25. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
26. Brealey N, Gupta A, Renaux J, et al. Pharmacokinetics of fluticasone furoate, umeclidinium and vilanterol as a triple therapy in healthy volunteers. Int J Clin Pharmacol Ther 2015; 53: 753-764.
27. Ferguson GT, Anzueto A, Fei A, et al. Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respir Med 2008; 102: 1099-1108.
28. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 776-789.
29. Dmitrienko A, Tamhane A, Wiens B. General multistage gatekeeping procedures. Biom J 2008; 50: 667-677.
30. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012; 67: 970-976.
31. Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015; 12: 27-34.
32. Vestbo J, Anderson J, Brook RD, et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013; 41: 1017-1022.